187 related articles for article (PubMed ID: 32479608)
1. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection.
Collins KA; Abd-Rahman AN; Marquart L; Ballard E; Gobeau N; Griffin P; Chalon S; Möhrle JJ; McCarthy JS
J Infect Dis; 2022 Mar; 225(6):1062-1069. PubMed ID: 32479608
[TBL] [Abstract][Full Text] [Related]
2. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
[TBL] [Abstract][Full Text] [Related]
3. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
McCarthy JS; Rückle T; Elliott SL; Ballard E; Collins KA; Marquart L; Griffin P; Chalon S; Möhrle JJ
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685476
[TBL] [Abstract][Full Text] [Related]
4. A randomized feasibility trial comparing four antimalarial drug regimens to induce
Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T
Elife; 2018 Feb; 7():. PubMed ID: 29482720
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.
McCarthy JS; Baker M; O'Rourke P; Marquart L; Griffin P; Hooft van Huijsduijnen R; Möhrle JJ
J Antimicrob Chemother; 2016 Sep; 71(9):2620-7. PubMed ID: 27272721
[TBL] [Abstract][Full Text] [Related]
6. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Collins KA; Wang CY; Adams M; Mitchell H; Rampton M; Elliott S; Reuling IJ; Bousema T; Sauerwein R; Chalon S; Möhrle JJ; McCarthy JS
J Clin Invest; 2018 Apr; 128(4):1551-1562. PubMed ID: 29389671
[TBL] [Abstract][Full Text] [Related]
7. Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria.
Woolley SD; Marquart L; Woodford J; Chalon S; Moehrle JJ; McCarthy JS; Barber BE
Malar J; 2021 Dec; 20(1):470. PubMed ID: 34930260
[TBL] [Abstract][Full Text] [Related]
8. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with
Collins KA; Rückle T; Elliott S; Marquart L; Ballard E; Chalon S; Griffin P; Möhrle JJ; McCarthy JS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30858218
[TBL] [Abstract][Full Text] [Related]
9. Spiroindolone KAE609 for falciparum and vivax malaria.
White NJ; Pukrittayakamee S; Phyo AP; Rueangweerayut R; Nosten F; Jittamala P; Jeeyapant A; Jain JP; Lefèvre G; Li R; Magnusson B; Diagana TT; Leong FJ
N Engl J Med; 2014 Jul; 371(5):403-10. PubMed ID: 25075833
[TBL] [Abstract][Full Text] [Related]
10. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
11. Liver Function Test Abnormalities in Experimental and Clinical
Odedra A; Webb L; Marquart L; Britton LJ; Chalon S; Moehrle JJ; Anstey NM; William T; Grigg MJ; Lalloo DG; Barber BE; McCarthy JS
Am J Trop Med Hyg; 2020 Nov; 103(5):1910-1917. PubMed ID: 32815508
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
13. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.
White NJ; Duong TT; Uthaisin C; Nosten F; Phyo AP; Hanboonkunupakarn B; Pukrittayakamee S; Jittamala P; Chuthasmit K; Cheung MS; Feng Y; Li R; Magnusson B; Sultan M; Wieser D; Xun X; Zhao R; Diagana TT; Pertel P; Leong FJ
N Engl J Med; 2016 Sep; 375(12):1152-60. PubMed ID: 27653565
[TBL] [Abstract][Full Text] [Related]
14. MEFAS, a hybrid of artesunate-mefloquine active against asexual stages of Plasmodium vivax in field isolates, inhibits malaria transmission.
Penna-Coutinho J; da Silva Araújo M; Campos Aguiar AC; Sá PM; Rios CT; Medeiros JF; Pereira DB; Boechat N; Krettli AU
Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():150-155. PubMed ID: 34637981
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
[TBL] [Abstract][Full Text] [Related]
16. Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence.
Tjitra E; Suprianto S; McBroom J; Currie BJ; Anstey NM
J Clin Microbiol; 2001 Mar; 39(3):1025-31. PubMed ID: 11230422
[TBL] [Abstract][Full Text] [Related]
17. Artefenomel: a promising new antimalarial drug.
Rosenthal PJ
Lancet Infect Dis; 2016 Jan; 16(1):6-8. PubMed ID: 26448142
[No Abstract] [Full Text] [Related]
18. Blood-stage dynamics and clinical implications of mixed Plasmodium vivax-Plasmodium falciparum infections.
Mason DP; McKenzie FE
Am J Trop Med Hyg; 1999 Sep; 61(3):367-74. PubMed ID: 10497972
[TBL] [Abstract][Full Text] [Related]
19. Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria.
Gansane A; Lingani M; Yeka A; Nahum A; Bouyou-Akotet M; Mombo-Ngoma G; Kaguthi G; Barceló C; Laurijssens B; Cantalloube C; Macintyre F; Djeriou E; Jessel A; Bejuit R; Demarest H; Marrast AC; Debe S; Tinto H; Kibuuka A; Nahum D; Mawili-Mboumba DP; Zoleko-Manego R; Mugenya I; Olewe F; Duparc S; Ogutu B
Malar J; 2023 Jan; 22(1):2. PubMed ID: 36597076
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
